These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 5982217)
21. The influence of host factors on drug response. VI. Hepatocellular diseases. Vesell ES Ration Drug Ther; 1981 Aug; 15(8):1-8. PubMed ID: 7347855 [No Abstract] [Full Text] [Related]
22. [Metabolic disturbances in chronic diseases of the biliary tracts and liver]. Kozlovskiĭ IV; Okorokov AN Vrach Delo; 1982 Aug; (8):22-4. PubMed ID: 6755904 [No Abstract] [Full Text] [Related]
23. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Chen BF; Liu CJ; Jow GM; Chen PJ; Kao JH; Chen DS Gastroenterology; 2006 Apr; 130(4):1153-68. PubMed ID: 16618410 [TBL] [Abstract][Full Text] [Related]
24. Factor VIII expression in liver disease. Hollestelle MJ; Geertzen HG; Straatsburg IH; van Gulik TM; van Mourik JA Thromb Haemost; 2004 Feb; 91(2):267-75. PubMed ID: 14961153 [TBL] [Abstract][Full Text] [Related]
25. [Immunohistochemistry in liver pathology]. Selves J; Voigt JJ; Reynes M Ann Pathol; 1995; 15(5):388-95. PubMed ID: 8540925 [No Abstract] [Full Text] [Related]
27. [Drug metabolism in patients with liver disease (author's transl)]. Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410 [TBL] [Abstract][Full Text] [Related]
28. [Effect of deferoxamine on urinary excretion of iron in chronic non-hemochromatosic liver diseases]. Brusa L; De Filippi PG; Cravario A Boll Soc Ital Biol Sper; 1967 Feb; 43(4):205-9. PubMed ID: 6055647 [No Abstract] [Full Text] [Related]
29. Hepatic proteoglycans--a brief survey of their pathobiochemical implications. Gressner AM Hepatogastroenterology; 1983 Dec; 30(6):225-9. PubMed ID: 6373541 [No Abstract] [Full Text] [Related]
30. [Circulation of ampicillin and sulfalene in liver disease patients]. Iakovlev VP; Bobrov VI; Gal'perin EI; Volkova NV; Nazarova OI Antibiotiki; 1982 Aug; 27(8):619-23. PubMed ID: 7125622 [No Abstract] [Full Text] [Related]
31. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Oh BK; Kim YJ; Park YN; Choi J; Kim KS; Park C Am J Gastroenterol; 2006 Apr; 101(4):831-8. PubMed ID: 16494581 [TBL] [Abstract][Full Text] [Related]
32. Peroxisomes (microbodies) in cell pathology. Goldfischer S; Reddy JK Int Rev Exp Pathol; 1984; 26():45-84. PubMed ID: 6400515 [No Abstract] [Full Text] [Related]
33. [Clinicolaboratory indices of hepatic coma in acute viral hepatitis and chronic liver diseases]. Postovit VA; Osipov LN; Zhurkin AT Vrach Delo; 1982 Aug; (8):116-9. PubMed ID: 7147867 [No Abstract] [Full Text] [Related]
34. Cytoplasmic p21(WAF1/CIP1) expression in human hepatocellular carcinomas. Shiraki K; Wagayama H Liver Int; 2006 Oct; 26(8):1018-9. PubMed ID: 16953844 [No Abstract] [Full Text] [Related]
35. Are patients with chronic liver disease hypermetabolic? Heymsfield SB; Waki M; Reinus J Hepatology; 1990 Mar; 11(3):502-5. PubMed ID: 2179099 [No Abstract] [Full Text] [Related]
36. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases. Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154 [TBL] [Abstract][Full Text] [Related]